WhatPeptide

Sermorelin

FDA-approved as GEREF for diagnosis and treatment of growth hormone deficiency in children (NDA 20-443, approved September 26, 1997). Voluntarily withdrawn from market June 2009 for commercial reasons — not for safety or efficacy concerns (Federal Register 78 FR 14095, March 4, 2013). Remains compoundable under Section 503A.

Strong evidence FDA Approved GH Secretagogue

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Approximately 11-12 minutes

Dosage range

200-500 mcg subcutaneously at bedtime (published research context)

Administration

Subcutaneous injection

Research level

Strong

How Sermorelin works

Sermorelin binds pituitary GHRH receptors on somatotroph cells, stimulating synthesis and pulsatile release of endogenous GH while preserving the natural feedback mechanisms of the hypothalamic-pituitary-somatotropic axis. Because it acts upstream to amplify endogenous GH pulses rather than directly replacing GH, sermorelin maintains physiological IGF-1 regulation and is associated with less risk of supraphysiological GH levels compared to exogenous somatropin. The half-life of approximately 11-12 minutes necessitates evening dosing to coincide with natural nocturnal GH secretory peaks.

Also known as: GRF 1-29, GHRH 1-29, Geref

Research relevance

GH Boost
Moderate relevance 75
Anti-Aging & Longevity
Moderate relevance 55
Muscle Growth
Moderate relevance 50

Side effects & safety

Injection site redness/swelling Flushing Headache Sleepiness

Contraindications

Active malignancy
Diabetic retinopathy
Pregnancy
Hypothyroidism (should be treated prior to therapy)

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Sermorelin? +
FDA-approved as GEREF for diagnosis and treatment of growth hormone deficiency in children (NDA 20-443, approved September 26, 1997). Voluntarily withdrawn from market June 2009 for commercial reasons — not for safety or efficacy concerns (Federal Register 78 FR 14095, March 4, 2013). Remains compoundable under Section 503A. Its mechanism of action is supported by robust clinical evidence.
What is Sermorelin researched for? +
Sermorelin has the strongest research relevance for GH Boost, Anti-Aging & Longevity, Muscle Growth. Evidence is supported by robust clinical evidence.
What are the side effects of Sermorelin? +
Reported side effects include Injection site redness/swelling, Flushing, Headache, Sleepiness. Key contraindications: Active malignancy; Diabetic retinopathy; Pregnancy; Hypothyroidism (should be treated prior to therapy).
Is Sermorelin FDA approved? +
Yes, Sermorelin has FDA approval for specific indications. Always consult a healthcare provider for appropriate use.
How is Sermorelin administered? +
Sermorelin is typically administered via subcutaneous route. Researched dosage range: 200-500 mcg subcutaneously at bedtime (published research context). Half-life: Approximately 11-12 minutes.

Explore similar peptides

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

CJC-1295 (No DAC)

Moderate evidence

GH Secretagogue

CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a shorter half-life than the DAC version, making it preferred for mimicking pulsatile physiological GH release when administered with a GHRP. It is widely used in research and wellness contexts for GH optimization.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

Tesamorelin

Strong evidence

GH Secretagogue

A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy.